Al-Mulla
Adam Al-Mulla, Kuwait KW
Patent application number | Description | Published |
---|---|---|
20090192243 | FLAME RETARDANT RESINOUS COMPOSITIONS AND PROCESS - Disclosed is a flame-retardant composition comprising (i) 40-66 wt. % alkenyl aromatic resin, (ii) 9-33 wt. % ammonium polyphosphate and (iii) 14-40 wt. % cellulosic material, wherein all weights are based on the total weight of the composition and wherein ammonium polyphosphate and cellulosic material are present in a weight % ratio effective to provide molded articles exhibiting at least V-1 flame rating as determined according to the UL-94 protocol. A process to prepare the composition and articles comprising a composition of the invention and/or made by the process of the invention described herein are also disclosed. | 07-30-2009 |
Fahd Al-Mulla, Safat KW
Patent application number | Description | Published |
---|---|---|
20090215038 | Prediction of Metastasis - The present invention relates to the prediction of metastasis by determining RKIP expression levels, and to products and kits adapted for such methods. In some embodiments, the present invention relates to methods of assigning a treatment or monitoring regime to a cancer patient according to the level of RKIP expression. | 08-27-2009 |
Fahd Al-Mulla, Al-Yarmouk KW
Patent application number | Description | Published |
---|---|---|
20130171273 | METHOD OF TREATING IMPAIRED WOUND HEALING IN DIABETICS - The method of treating impaired wound healing in diabetics comprises the step of administering an effective amount of a glycogen synthase kinase 3-β (GSK-3β) inhibitor to a diabetic patient in need thereof to activate the NF-E2-related factor 2 (Nrf2) and genes downstream of Nrf2 that normally regulate the expression and coordination of antioxidant responses during wound healing, but are suppressed in the diabetic patient undergoing the oxidative stress that can occur during wound healing. The GSK-3β inhibitor may be lithium or a pharmaceutically acceptable salt thereof, or TDZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione). The method may further comprise the step of testing the diabetic patient for the presence of oxidative stress and decreased Nrf2, which enables the early or prophylactic treatment of the patient with a GSK-3β inhibitor when the patient first presents with a wound, rather than waiting for other symptoms of impaired wound healing to occur. | 07-04-2013 |
20130172253 | METHOD OF DIAGNOSING AND TREATING OXIDATIVE STRESS-IMPAIRED WOUND HEALING - The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing. | 07-04-2013 |
20130172256 | METHOD OF TREATING DIABETES-RELATED IMPAIRED WOUND HEALING - The method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of estrogen replacement therapy to a patient in need thereof to promote wound healing. Alternatively, the method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of a TNF-α inhibitor to a patient in need thereof to promote wound healing. The method of treating diabetes-related impaired wound healing may also include both the step of administering an effective amount of estrogen replacement therapy and administering an effective amount of a TNF-α inhibitor to a patient in need thereof to promote wound healing. | 07-04-2013 |
20150080236 | METHOD OF SUB-CLASSIFYING BREAST CANCER TUMORS - The method of sub-classifying breast cancer tumors profiles the expression of the Raf kinase inhibitor protein (RKIP) from a tissue sample from a cancerous primary breast tumor. The RKIP expression is profiled using its mRNA or by immunohistochemical protein quantifying methods in order to detect the level of RKIP in the breast cancer tissue sample. Based upon the RKIP expression profile, a sub-classification of cancer type may then be assigned. An RKIP expression of approximately 10.31 indicates basal carcinoma, an RKIP expression of approximately 10.04 indicates Claudin-low carcinoma, an RKIP expression of approximately 10.47 indicates Luminal-A carcinoma, an RKIP expression of approximately 10.44 indicates Luminal-B carcinoma, an RKIP expression of approximately 10.25 indicates HER2+ carcinoma, an RKIP expression of approximately 10.43 indicates ER+ carcinoma, and an RKIP expression of approximately 10.30 indicates ER− carcinoma. | 03-19-2015 |
20150352064 | METHOD OF TREATING DELAYED HEALING OF A WOUND ASSOCIATED WITH DIABETES - The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer. | 12-10-2015 |
Fahd Al-Mulla, Yarmouk KW
Patent application number | Description | Published |
---|---|---|
20160068912 | METHOD FOR DETERMINING RISK OF METASTATIC RELAPSE IN A PATIENT DIAGNOSED WITH COLORECTAL CANCER - The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene. | 03-10-2016 |
Muath Al-Mulla, Dammam SA
Patent application number | Description | Published |
---|---|---|
20150185361 | COMPUTER-IMPLEMENTED METHODS FOR RESERVOIR SIMULATION WITH AUTOMATED WELL COMPLETIONS AND RESERVOIR GRID DATA QUALITY ASSURANCE - Machine, computer readable medium, program code, and computer-implemented methods for performing a reservoir simulation with well completion and reservoir grid data quality assurance, are provided. An exemplary embodiment can include a data quality analyzing machine having memory containing data quality analyzing instructions configured to simulate a reservoir model with automated well completion and reservoir grid data quality assurance. | 07-02-2015 |
20150185364 | MACHINES FOR RESERVOIR SIMULATION WITH AUTOMATED WELL COMPLETIONS AND RESERVOIR GRID DATA QUALITY ASSURANCE - Machine, computer readable medium, program code, and computer-implemented methods for performing a reservoir simulation with well completion and reservoir grid data quality assurance, are provided. An exemplary embodiment can include a data quality analyzing machine having memory containing data quality analyzing instructions configured to simulate a reservoir model with automated well completion and reservoir grid data quality assurance. | 07-02-2015 |
Udai M. Al-Mulla, Dammam SA
Patent application number | Description | Published |
---|---|---|
20110131114 | METHODS FOR MANAGING CONTRACT PROCUREMENT - Computer implemented methods of facilitating contract procurement and contract management through an online contract procurement and management website. An example of a computer implemented method includes assigning a personalized contracting entity member user web page to each of a plurality of contracting entity member users associated with a contracting entity, and assigning a personalized contractor member user home web page to each of a plurality of contractor member users associated with a plurality of potential contractors. The personalized contracting entity member user web pages can provide centralized access to perform contract procurement functions for each of the virtual contract rooms associated with the respective contracting entity member users. The personalized contractor member user web pages can provide consolidated contract room access and consolidated contract room task and communication review for each of the virtual contract rooms associated with the respective contractor member users. | 06-02-2011 |